In the five years since the FDA's initial approval of chimeric antigen receptor (CAR) T cell therapy, Penn Medicine has gleaned 20 additional approvals related to drugs and techniques to treat or detect cancer.
May 29, 2023
0
33
Men ages 55 to 69 should talk with their health care provider about prostate-specific antigen (PSA)-based screening for prostate cancer. That's according to new recommendations from the U.S. Preventive Services Task Force.
Apr 17, 2017
0
4
CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ...
Feb 6, 2023
0
17
A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional ...
May 16, 2011
0
0
Acute myeloid leukemia (AML) is a type of blood cancer that forms in the soft marrow of the bones, typically attacking cells that would otherwise form the key component of the body's immunodefense system, white blood cells.
May 3, 2024
0
13
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.
Jan 22, 2018
0
250
Alberta men with elevated prostate-specific antigen (PSA) levels can now take a new blood test to determine their risk for clinically significant prostate cancer and potentially avoid an unnecessary biopsy.
Oct 6, 2023
0
30
A researcher from Hull York Medical School (HYMS) has helped design and set up a study which has been hailed as the biggest leap in diagnosing prostate cancer in decades.
Jan 31, 2017
0
12
When non-invasive sound waves break apart tumors, they trigger an immune response in mice. By breaking down the cell wall "cloak," the treatment exposes cancer cell markers that had previously been hidden from the body's ...
Jan 31, 2023
0
50
The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men.
Jun 10, 2023
0
5
